Advertisement
| ceo american cancer society: The Cancer Atlas Ahmedin Jemal, 2015 This atlas illustrates the latest available data on the cancer epidemic, showing causes, stages of development, and prevalence rates of different types of cancers by gender, income group, and region. It also examines the cost of the disease, both in terms of health care and commercial interests, and the steps being taken to curb the epidemic, from research and screening to cancer management programs and health education. |
| ceo american cancer society: A New Deal for Cancer Abbe R. Gluck, Charles S Fuchs, 2021-11-16 An unprecedented constellation of experts—leading cancer doctors, policymakers, cutting-edge researchers, national advocates, and more—explore the legacy and the shortcomings from the fifty-year war on cancer and look ahead to the future. The longest war in the modern era, longer than the Cold War, has been the war on cancer. Cancer is a complex, evasive enemy, and there was no quick victory in the fight against it. But the battle has been a monumental test of medical and scientific research and fundraising acumen, as well as a moral and ethical challenge to the entire system of medicine. In A New Deal for Cancer, some of today’s leading thinkers, activists, and medical visionaries describe the many successes in the long war and the ways in which our deeper failings as a society have held us back from a more complete success. Together they present an unrivaled and nearly complete map of the battlefield across dimensions of science, government, equity, business, the patient provider experience, and more, documenting our emerging understanding of cancer’s many unique dimensions and offering bold new plans to enable the American health care system to deliver progress and hope to all patients. |
| ceo american cancer society: Advancing the Science of Cancer in Latinos Amelie G. Ramirez, Edward J. Trapido, 2019-11-21 This open access book gives an overview of the sessions, panel discussions, and outcomes of the Advancing the Science of Cancer in Latinos conference, held in February 2018 in San Antonio, Texas, USA, and hosted by the Mays Cancer Center and the Institute for Health Promotion Research at UT Health San Antonio. Latinos – the largest, youngest, and fastest-growing minority group in the United States – are expected to face a 142% rise in cancer cases in coming years. Although there has been substantial advancement in cancer prevention, screening, diagnosis, and treatment over the past few decades, addressing Latino cancer health disparities has not nearly kept pace with progress. The diverse and dynamic group of speakers and panelists brought together at the Advancing the Science of Cancer in Latinos conference provided in-depth insights as well as progress and actionable goals for Latino-focused basic science research, clinical best practices, community interventions, and what can be done by way of prevention, screening, diagnosis, and treatment of cancer in Latinos. These insights have been translated into the chapters included in this compendium; the chapters summarize the presentations and include current knowledge in the specific topic areas, identified gaps, and top priority areas for future cancer research in Latinos. Topics included among the chapters: Colorectal cancer disparities in Latinos: Genes vs. Environment Breast cancer risk and mortality in women of Latin American origin Differential cancer risk in Latinos: The role of diet Overcoming barriers for Latinos on cancer clinical trials Es tiempo: Engaging Latinas in cervical cancer research Emerging policies in U.S. health care Advancing the Science of Cancer in Latinos proves to be an indispensable resource offering key insights into actionable targets for basic science research, suggestions for clinical best practices and community interventions, and novel strategies and advocacy opportunities to reduce health disparities in Latino communities. It will find an engaged audience among researchers, academics, physicians and other healthcare professionals, patient advocates, students, and others with an interest in the broad field of Latino cancer. |
| ceo american cancer society: Centers of the Cancer Universe Donald L. Trump, Eric T. Rosenthal, 2021-10-11 A 2022 Choice Reviews Outstanding Academic Title An important history of the development of cancer centers of excellence and the revolution in cancer treatment. In the 1960s a coalition of concerned citizens, scientists and politicians joined forces to convince the federal government to focus its efforts on conquering cancer. The National Cancer Act of 1971 resulted and was signed into law on December 23, 1971 by President Nixon. The national “War on Cancer,” was declared with some leaders naively arguing that the disease would be conquered by the nation’s bicentennial—a mere five years in the future. Over the next five decades scientific discoveries demonstrated the great complexity of what had formerly been thought of as a single disease – with the advent of the genetic characterization of cancers, it is now recognized that there are almost an infinite number of cancers as defined by their many genetic mutations. The National Cancer Act established the infrastructure for the designation of centers by the National Cancer Institute (NCI) and these centers have evolved into models of multidisciplinary, collaborative cancer research, treatment and prevention contributing to a reduction in cancer mortality and increase in quality of life and survival that has translated into more than 17 million cancer survivors in the United States in 2021. Centers of the Cancer Universe: A Half-Century of Progress Against Cancer tells the story of how cancer research was not front and center at most universities and research institutions before the National Cancer Act of 1971, and why many physicians were reluctant even to treat patients with cancer in the early 20th century. It follows the behind-the-scenes lobbying, resistance and negotiating that preceded signing the Act into law, and how the cancer centers of today came to fruition, and shaped how cancer research, clinical trials and treatment would be conducted. |
| ceo american cancer society: Applying Big Data to Address the Social Determinants of Health in Oncology National Academies of Sciences, Engineering, and Medicine, Division on Engineering and Physical Sciences, Committee on Applied and Theoretical Statistics, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2020-08-14 The National Academies of Sciences, Engineering, and Medicine held the workshop Applying Big Data to Address the Social Determinants of Health in Oncology on October 28â€29, 2019, in Washington, DC. This workshop examined social determinants of health (SDOH) in the context of cancer, and considered opportunities to effectively leverage big data to improve health equity and reduce disparities. The workshop featured presentations and discussion by experts in technology, oncology, and SDOH, as well as representatives from government, industry, academia, and health care systems. This publication summarizes the presentations and discussions from the workshop. |
| ceo american cancer society: Uncharitable Dan Pallotta, 2010 A courageous call to free charity from its ideological and economic constraints |
| ceo american cancer society: The Emperor of All Maladies Siddhartha Mukherjee, 2011-08-09 Winner of the Pulitzer Prize and a documentary from Ken Burns on PBS, this New York Times bestseller is “an extraordinary achievement” (The New Yorker)—a magnificent, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer. |
| ceo american cancer society: The Drug Development Paradigm in Oncology National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2018-02-12 Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop. |
| ceo american cancer society: Passion Capital Paul Alofs, 2013-01-15 Passion Capital is a revolutionary asset that will completely change your idea of how to build long-term success for your career, company, or cause. Ask leaders in any country this essential question: What is your most valuable asset? and they may suggest one of three traditional forms of capital - financial, human, or intellectual. These are intelligent, well-meaning answers, but they are also completely wrong. More valuable than money, human resources, and intellectual property, Passion Capital is what separates leaders from followers, and innovators from imitators. It is the foundation upon which all other forms of capital are built. Passion is an emotion, but Passion Capital is tangible. It is the energy, intensity, and sustainability leaders use to build lasting value and competitive advantage. Organizations that possess Passion Capital - Apple, Johnson & Johnson, Four Seasons Hotels, the Montreal Canadiens, among others - lead their sectors, while those that rely on established forms of capital may get stuck in neutral and fail to achieve their full potential. Passion Capital presents seven principles for growing and investing in this new asset class and includes over fifty insightful stories drawn from business, not-for-profit, the arts sector, and politics. In this groundbreaking book, veteran business leader Paul Alofs ushers in a whole new way of thinking about the very definition of success and reveals how to acquire the world's most valuable asset and apply it to your career, company, or cause. |
| ceo american cancer society: A Voice for Nonprofits Jeffrey M. Berry, 2023-07-31 Nonprofit organizations are playing an increasingly important role in delivering basic government services. Yet they are discouraged by federal law from participating in legislative lobbying efforts—even on issues that affect their clients directly. Without the involvement of nonprofits in the governmental process, the vulnerable populations they serve are left without effective representation in the political system. A Voice for Nonprofits analyzes the effect of government restrictions on the participation of nonprofits in the policymaking process and suggests ways to address the problems. The relationship between nonprofits and the government is ideal in many respects, according to Jeffrey M. Berry and David F. Arons. By underwriting operating budgets and subcontracting the administration of programs to nonprofits, governments at all levels are able to take advantage of nonprofits' dedication, imagination, and private fund-raising skills. However, as nonprofits assume greater responsibility for delivering services traditionally provided by government, that responsibility is not matched by a congruous increase in policy influence. Berry and Arons believe the lobbying restrictions should be eased so that nonprofits may become more involved in public policymaking. Their recommendations are designed to ensure that nonprofit organizations—and the constituencies they serve—are effectively represented in the American political system. |
| ceo american cancer society: Sharing Clinical Research Data Institute of Medicine, Board on Health Care Services, Board on Health Sciences Policy, Roundtable on Translating Genomic-Based Research for Health, National Cancer Policy Forum, Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, 2013-06-07 Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organizations may represent lost opportunities in biomedical research. Despite the potential benefits that could be accrued from pooling and analysis of shared data, barriers to data sharing faced by researchers in industry include concerns about data mining, erroneous secondary analyses of data, and unwarranted litigation, as well as a desire to protect confidential commercial information. Academic partners face significant cultural barriers to sharing data and participating in longer term collaborative efforts that stem from a desire to protect intellectual autonomy and a career advancement system built on priority of publication and citation requirements. Some barriers, like the need to protect patient privacy, pre- sent challenges for both sectors. Looking ahead, there are also a number of technical challenges to be faced in analyzing potentially large and heterogeneous datasets. This public workshop focused on strategies to facilitate sharing of clinical research data in order to advance scientific knowledge and public health. While the workshop focused on sharing of data from preplanned interventional studies of human subjects, models and projects involving sharing of other clinical data types were considered to the extent that they provided lessons learned and best practices. The workshop objectives were to examine the benefits of sharing of clinical research data from all sectors and among these sectors, including, for example: benefits to the research and development enterprise and benefits to the analysis of safety and efficacy. Sharing Clinical Research Data: Workshop Summary identifies barriers and challenges to sharing clinical research data, explores strategies to address these barriers and challenges, including identifying priority actions and low-hanging fruit opportunities, and discusses strategies for using these potentially large datasets to facilitate scientific and public health advances. |
| ceo american cancer society: The Tobacco Atlas Judith Mackay, Michael P. Eriksen, 2002 Research in the past five years suggests a bleak picture of the health dangers of smoking, with tobacco the biggest single killer of all forms of pollution. It is estimated that one person dies every ten seconds due to smoking-related diseases. This publication considers the history and current position regarding tobacco use, as well as providing some predictions for the future of the tobacco epidemic upto the year 2050. It contains a number of full-colour world maps and graphics to illustrate the variations between countries and regions. Issues discussed include: tobacco prevalence and consumption; youth smoking; the economics of tobacco farming and manufacturing; smuggling; the tobacco industry, promotion, profits and trade; smokers' rights; legislative action such as smoke-free areas, tobacco advertising bans and health warnings. |
| ceo american cancer society: Moving Through Cancer D. Kathryn Schmitz, 2021-10-19 Cancer diagnosis and treatment doesn't have to be a passive experience, and it shouldn't be. Dr. Kathryn Schmitz's Moving Through Cancer introduces a 21-day program of strength training and exercise for cancer prevention and recovery. Go from diagnosis to thriving with this empowering guide to using strength training and exercise to improve your mental and physical health before, during, and after cancer diagnosis and treatment. This groundbreaking program will show you how to use exercise and movement to: • Recover more quickly from surgery • Withstand chemotherapy (or other drug treatments) or radiation with fewer side effects • Bounce back to daily life following cancer treatments • Prevent loss of function or fitness due to treatment • Return to work more quickly or stay at work throughout treatment • Protect against late side effects of treatment that come years after diagnosis Leading exercise oncology researcher Dr. Kathryn Schmitz shows you how to prepare for cancer treatment and begin regularly exercising in just 21 days using five key steps: Move, Lift, Eat, Sleep, and Log. Both informative and practical, Moving Through Cancer explains the science of healing and prevention and delivers a paradigm-shifting message for patients, doctors, and caregivers about using exercise to live with and beyond cancer. FOR READERS OF: Anticancer Living and The Cancer-Fighting Kitchen. A PRACTITIONER AND CAREGIVER: Dr. Kathryn Schmitz is a pracademic (practitioner + academic) and a caregiver: In 2010, the publication of one of her trials in The New England Journal of Medicine and the Journal of the American Medical Association overturned years of entrenched dogma and conventional wisdom that told breast cancer survivors to avoid upper body exercise. In 2016, Dr. Schmitz's wife, Sara, was diagnosed with stage 3 squamous cell carcinoma—she is currently NED (no evidence of disease) and cancer free. Moving Through Cancer is inspired by Dr. Schmitz's professional and personal experience with cancer. HELPS PATIENTS AND CAREGIVERS TO COMBAT THE POWERLESSNESS OF THE CANCER JOURNEY: Dr. Schmitz's empowering message will not only resonate with anyone who has been diagnosed with cancer but with their family and loved ones as well. Dr. Schmitz is able to give life back to readers by providing results that include better sleep, better sex, less chemo brain, reduced nausea, and improved recovery. PARADIGM-SHIFTING PROTOCOL: Moving Through Cancer is the center of Dr. Schmitz's campaign to have doctors prescribing exercise to cancer patients as common practice by 2029. THE FIRST MAINSTREAM EXERCISE-FOR-CANCER BOOK: Until now, exercise-for-cancer books have been limited to academic approaches or one-cancer-specific (breast) or one-exercise specific (yoga, pilates) books. Moving Through Cancer is for all cancer patients and survivors and their caregivers. GREAT FOR THE CLASSROOM: Students and teachers will want to use these techniques in their classrooms to provide a better understanding of how to treat cancer patients. Perfect for: 18+, Health enthusiasts, rehab, exercise, academia, medical professionals |
| ceo american cancer society: National Cancer Institute and American Cancer Society Samuel S. Epstein, 2011-05-17 |
| ceo american cancer society: Reclaiming Your Life After Diagnosis Kim Thiboldeaux, Mitch Golant, 2012-06-05 A Comprehensive and Compassionate Approach to Cancer Care Reclaiming Your Life After Diagnosis is packed with incredible information and resources to get you or someone you love through the challenging journey of a cancer diagnosis and treatment. This book accurately and compassionately addresses the physical, emotional, social and practical needs of cancer patients and their support systems. Find out how to: Put an effective support and resource team in place to buffer against the challenges of diagnosis and treatment Build a community to deal with the daunting decisions treatment requires Develop practical, more effective ways to manage side effects Deal with complex emotional issues ranging from the shock of initial diagnosis to creating a living legacy and a meaning-filled life Through powerful, first-person testimony, as well as a plethora of the best tips, evidence-based research, treatment and support information currently available, Reclaiming Your Life After Diagnosis will help cancer patients develop the strength and empowerment they need to stay focused on healing—and to develop the mindset of a survivor. |
| ceo american cancer society: Golden Holocaust Robert N. Proctor, 2012-02-28 The cigarette is the deadliest artifact in the history of human civilization. It is also one of the most beguiling, thanks to more than a century of manipulation at the hands of tobacco industry chemists. In Golden Holocaust, Robert N. Proctor draws on reams of formerly-secret industry documents to explore how the cigarette came to be the most widely-used drug on the planet, with six trillion sticks sold per year. He paints a harrowing picture of tobacco manufacturers conspiring to block the recognition of tobacco-cancer hazards, even as they ensnare legions of scientists and politicians in a web of denial. Proctor tells heretofore untold stories of fraud and subterfuge, and he makes the strongest case to date for a simple yet ambitious remedy: a ban on the manufacture and sale of cigarettes. |
| ceo american cancer society: Cosmetic Breast Surgery Sameer A. Patel, 2020 |
| ceo american cancer society: The Hacking of the American Mind Robert H. Lustig, 2017-09-12 Explores how industry has manipulated our most deep-seated survival instincts.—David Perlmutter, MD, Author, #1 New York Times bestseller, Grain Brain and Brain Maker The New York Times–bestselling author of Fat Chance reveals the corporate scheme to sell pleasure, driving the international epidemic of addiction, depression, and chronic disease. While researching the toxic and addictive properties of sugar for his New York Times bestseller Fat Chance, Robert Lustig made an alarming discovery—our pursuit of happiness is being subverted by a culture of addiction and depression from which we may never recover. Dopamine is the “reward” neurotransmitter that tells our brains we want more; yet every substance or behavior that releases dopamine in the extreme leads to addiction. Serotonin is the “contentment” neurotransmitter that tells our brains we don’t need any more; yet its deficiency leads to depression. Ideally, both are in optimal supply. Yet dopamine evolved to overwhelm serotonin—because our ancestors were more likely to survive if they were constantly motivated—with the result that constant desire can chemically destroy our ability to feel happiness, while sending us down the slippery slope to addiction. In the last forty years, government legislation and subsidies have promoted ever-available temptation (sugar, drugs, social media, porn) combined with constant stress (work, home, money, Internet), with the end result of an unprecedented epidemic of addiction, anxiety, depression, and chronic disease. And with the advent of neuromarketing, corporate America has successfully imprisoned us in an endless loop of desire and consumption from which there is no obvious escape. With his customary wit and incisiveness, Lustig not only reveals the science that drives these states of mind, he points his finger directly at the corporations that helped create this mess, and the government actors who facilitated it, and he offers solutions we can all use in the pursuit of happiness, even in the face of overwhelming opposition. Always fearless and provocative, Lustig marshals a call to action, with seminal implications for our health, our well-being, and our culture. |
| ceo american cancer society: How We Do Harm Otis Webb Brawley, MD, Paul Goldberg, 2012-01-31 A startling and important exposé on the state of medicine, research, and healthcare today by the Chief Medical and Scientific Officer of the American Cancer Society How We Do Harm exposes the underbelly of healthcare today—the overtreatment of the rich, the under treatment of the poor, the financial conflicts of interest that determine the care that physicians' provide, insurance companies that don't demand the best (or even the least expensive) care, and pharmaceutical companies concerned with selling drugs, regardless of whether they improve health or do harm. Dr. Otis Brawley is the chief medical and scientific officer of The American Cancer Society, an oncologist with a dazzling clinical, research, and policy career. How We Do Harm pulls back the curtain on how medicine is really practiced in America. Brawley tells of doctors who select treatment based on payment they will receive, rather than on demonstrated scientific results; hospitals and pharmaceutical companies that seek out patients to treat even if they are not actually ill (but as long as their insurance will pay); a public primed to swallow the latest pill, no matter the cost; and rising healthcare costs for unnecessary—and often unproven—treatments that we all pay for. Brawley calls for rational healthcare, healthcare drawn from results-based, scientifically justifiable treatments, and not just the peddling of hot new drugs. Brawley's personal history – from a childhood in the gang-ridden streets of black Detroit, to the green hallways of Grady Memorial Hospital, the largest public hospital in the U.S., to the boardrooms of The American Cancer Society—results in a passionate view of medicine and the politics of illness in America - and a deep understanding of healthcare today. How We Do Harm is his well-reasoned manifesto for change. |
| ceo american cancer society: Facilitating Interdisciplinary Research Institute of Medicine, National Academy of Engineering, National Academy of Sciences, Committee on Science, Engineering, and Public Policy, Committee on Facilitating Interdisciplinary Research, 2005-04-04 Facilitating Interdisciplinary Research examines current interdisciplinary research efforts and recommends ways to stimulate and support such research. Advances in science and engineering increasingly require the collaboration of scholars from various fields. This shift is driven by the need to address complex problems that cut across traditional disciplines, and the capacity of new technologies to both transform existing disciplines and generate new ones. At the same time, however, interdisciplinary research can be impeded by policies on hiring, promotion, tenure, proposal review, and resource allocation that favor traditional disciplines. This report identifies steps that researchers, teachers, students, institutions, funding organizations, and disciplinary societies can take to more effectively conduct, facilitate, and evaluate interdisciplinary research programs and projects. Throughout the report key concepts are illustrated with case studies and results of the committee's surveys of individual researchers and university provosts. |
| ceo american cancer society: Cancer Care for the Whole Patient Institute of Medicine, Board on Health Care Services, Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting, 2008-03-19 Cancer care today often provides state-of-the-science biomedical treatment, but fails to address the psychological and social (psychosocial) problems associated with the illness. This failure can compromise the effectiveness of health care and thereby adversely affect the health of cancer patients. Psychological and social problems created or exacerbated by cancer-including depression and other emotional problems; lack of information or skills needed to manage the illness; lack of transportation or other resources; and disruptions in work, school, and family life-cause additional suffering, weaken adherence to prescribed treatments, and threaten patients' return to health. Today, it is not possible to deliver high-quality cancer care without using existing approaches, tools, and resources to address patients' psychosocial health needs. All patients with cancer and their families should expect and receive cancer care that ensures the provision of appropriate psychosocial health services. Cancer Care for the Whole Patient recommends actions that oncology providers, health policy makers, educators, health insurers, health planners, researchers and research sponsors, and consumer advocates should undertake to ensure that this standard is met. |
| ceo american cancer society: Women of the Vine Deborah Brenner, 2007-01-22 This book takes you on a very different journey to wine country, inviting you to enjoy the remarkable stories of twenty dynamic women in the world of wine. These women share their lives, wine tips, pairings, and most important, enthusiasm for wine while imparting their rich life lessons and wine expertise—a wonderful way to share your love for wine with the enterprising women who help bring it to your table. |
| ceo american cancer society: Augie's Quest Augie Nieto, T.R. Pearson, 2011-01-15 What happens to orphan diseases that aren't big enough profit centers for the pharmaceutical industry or get caught in the web of government funding and academic research? Augie Nieto found out in the spring of 2005: At forty-seven years old he was diagnosed with ALS. Devastated, Augie struggled with depression and attempted suicide. When he awoke from a coma, with friends and family surrounding him, his sense of faith and mission were renewed. Fast-forward one year: Augie and his wife, Lynne, were profiled as Real Heroes on the Today show. Their determination to beat the disease had already led to major overhauls in the way ALS research was conducted. In partnership with the Muscular Dystrophy Association, Augie had set up a foundation and lab to coordinate and oversee ALS research and testing across the globe. By centralizing operations and championing an entrepreneurial approach to medical research, Augie and his team accomplished remarkable results in less than two years. Part inspiration, part business innovation, Augie's Quest illustrates how one person can make a meaningful difference. Praise for Augie Nieto: George H. W. Bush, former U.S. president: Your contributions to the fitness industry are well known, and your dedication an inspiration. Lance Armstrong, seven-time Le Tour de France champion: I think it says a lot about Augie, the fact that everybody came together regardless of whether or not it's for competing gyms or competing companies that make equipment. They all say, this is one of our own; this is a guy who's committed his life to our industry and has been dealt a serious blow. We're going to be there for him, we're going to say, we're here for you and we're part of the Quest. Arnold Schwarzenegger, governor of California: Your success has been incredible. But you are so much more than just a successful businessman. You are the greatest husband, a great father, and a terrific friend. So, |
| ceo american cancer society: The Bad Food Bible Aaron E. Carroll, 2017 Reveals the positive benefits of enjoying moderate portions of vilified ingredients ranging from red meat and alcohol to gluten and salt. |
| ceo american cancer society: The Man in the Arena: Surviving Multiple Myeloma Since 1992 James D. Bond, 2021-03-20 James Bond's survival of multiple myeloma since 1992 is an amazing story of tenacity, hard work and good fortune. In this book Jim shares his and his caregiver wife's, Kathleen, approaches and experiences and difficulties. This book provides two acronyms Jim developed that summarize their approaches to surviving a deadly, incurable blood cancer. Multiple myeloma's average survival is about 5 years. There is no cure, yet. Jim primarily is treated in Cleveland at University Hospital's Seidman Cancer Center and the Dana Farber Cancer Institute in Boston, with second opinions from Mayo Clinic and Mass. General doctors specializing in multiple myeloma. They continue to share their story, which they have done in over 30 US states, Washing DC at the National Academy of Science, and in Canada, Spain and Japan. They welcome opportunities to help other multiple myeloma patients and caregivers by sharing their experiences. They do not give medical or drug advice in their talks nor in this book. They live in greater Cleveland, Ohio and enjoy their 2 grown boys, their wives, and 3 grandchildren. Searching Jim's name and multiple myeloma provides much of their story and contact information. |
| ceo american cancer society: Oxford Textbook of Cancer Biology Francesco Pezzella, Mahvash Tavassoli, David Kerr, 2019-05-02 The study of the biology of tumours has grown to become markedly interdisciplinary, involving chemists, statisticians, epidemiologists, mathematicians, bioinformaticians, and computer scientists alongside biologists, geneticists, and clinicians. The Oxford Textbook of Cancer Biology brings together the most up-to-date developments from different branches of research into one coherent volume, providing a comprehensive and current account of this rapidly evolving field. Structured in eight sections, the book starts with a review of the development and biology of multi-cellular organisms, how they maintain a healthy homeostasis in an individual, and a description of the molecular basis of cancer development. The book then illustrates, as once cells become neoplastic, their signalling network is altered and pathological behaviour follows. It explores the changes that cancer cells can induce in nearby normal tissue, the new relationship established between them and the stroma, and the interaction between the immune system and tumour growth. The authors illustrate the contribution provided by high throughput techniques to map cancer at different levels, from genomic sequencing to cellular metabolic functions, and how information technology, with its vast amounts of data, is integrated with traditional cell biology to provide a global view of the disease. The effect of the different types of treatments on the biology of the neoplastic cells are explored to understand on the one side, why some treatments succeed, and on the other, how they can affect the biology of resistant and recurrent disease. The book concludes by summarizing what we know to date about cancer, and in what direction our understanding of cancer is moving. Edited by leading authorities in the field with an international team of contributors, this book is an essential resource for scholars and professionals working in the wide variety of sub-disciplines that make up today's cancer research and treatment community. It is written not only for consultation, but also for easy cover-to-cover reading. |
| ceo american cancer society: Cancer as a Metabolic Disease Thomas Seyfried, 2012-05-18 The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism. However, Warburg did not link his theory to the hallmarks of cancer and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention. Support for this position is derived from critical assessment of current cancer theories. Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. |
| ceo american cancer society: American Cancer Society's Complete Guide to Prostate Cancer David G. Bostwick, 2005 A complete guide to Prostate Cancer. |
| ceo american cancer society: Advances in Radiation Oncology Jeffrey Y.C. Wong, Timothy E. Schultheiss, Eric H. Radany, 2017-04-20 This book concisely reviews important advances in radiation oncology, providing practicing radiation oncologists with a fundamental understanding of each topic and an appreciation of its significance for the future of radiation oncology. It explores in detail the impact of newer imaging modalities, such as multiparametric magnetic resonance imaging (MRI) and positron emission tomography (PET) using fluorodeoxyglucose (FDG) and other novel agents, which deliver improved visualization of the physiologic and phenotypic features of a given cancer, helping oncologists to provide more targeted radiotherapy and assess the response. Due consideration is also given to how advanced technologies for radiation therapy delivery have created new treatment options for patients with localized and metastatic disease, highlighting the increasingly important role of image-guided radiotherapy in treating systemic and oligometastatic disease. Further topics include the potential value of radiotherapy in enhancing immunotherapy thanks to the broader immune-stimulatory effects, how cancer stem cells and the tumor microenvironment influence response, and the application of mathematical and systems biology methods to radiotherapy. |
| ceo american cancer society: The SAGE Encyclopedia of Cancer and Society Graham A. Colditz, 2015-08-12 The first edition of the Encyclopedia of Cancer and Society was published in 2007 and received a 2008 Editors’ Choice Award from Booklist. It served as a general, non-technical resource focusing on cancer from the perspective of the social and behavioral sciences, exploring social and economic impacts, the “business” of cancer, advertising of drugs and treatment centers, how behavior change could offer great potential for cancer prevention, environmental risks, food additives and regulation, the relation between race and ethnicity and cancer risk, socioeconomic status, controversies—both scientific and political—in cancer treatment and research, country-by-country entries on cancer around the world, and more. Given various developments in the field including new drug treatments, political controversies over use of the vaccines Gardasil and Cervarix with young girls to prevent cervical cancer, and unexpected upticks in the prevalence of adult smoking within the U.S. following decades of decline, the SAGE Encyclopedia of Cancer and Society, Second Edition serves as an updated and more current encyclopedia that addresses concerns pertaining to this topic. Key Features: · Approximately half of the 700 first-edition articles revised and updated · 30+ new entries covering new developments since 2006 · Signed entries with cross-references · Further Readings accompanied by pedagogical elements · New Reader’s Guide · Updated Chronology, Resource Guide, Glossary, and through new Index The SAGE Encyclopedia of Cancer and Society, Second Edition serves as a reliable and precise source for students and researchers with an interest in social and behavioral sciences and seeks to better understand the continuously evolving subject matter of cancer and society. |
| ceo american cancer society: Handbook of Health Economics A J. Culyer, J.P. Newhouse, 2000-07-19 The Handbook of Health Economics provide an up-to-date survey of the burgeoning literature in health economics. As a relatively recent subdiscipline of economics, health economics has been remarkably successful. It has made or stimulated numerous contributions to various areas of the main discipline: the theory of human capital; the economics of insurance; principal-agent theory; asymmetric information; econometrics; the theory of incomplete markets; and the foundations of welfare economics, among others. Perhaps it has had an even greater effect outside the field of economics, introducing terms such as opportunity cost, elasticity, the margin, and the production function into medical parlance. Indeed, health economists are likely to be as heavily cited in the clinical as in the economics literature. Partly because of the large share of public resources that health care commands in almost every developed country, health policy is often a contentious and visible issue; elections have sometimes turned on issues of health policy. Showing the versatility of economic theory, health economics and health economists have usually been part of policy debates, despite the vast differences in medical care institutions across countries. The publication of the first Handbook of Health Economics marks another step in the evolution of health economics. |
| ceo american cancer society: Cancer in Sub-Saharan Africa D. M. Parkin, J. Ferlay, A. Jemal, M. Borok, S. S. Manraj, G. G. N'Da, F. Bray, B. Liu, F. J. Ogunbiyi, 2018 The Cancer in Sub-Saharan Africa volume brings together population-based cancer incidence data from 25 cancer registries in 20 sub-Saharan African countries that are part of the African Cancer Registry Network. The compiled data in this volume, presented and commented upon by covered population and by anatomical site, are of tremendous value to the assessment of the pattern and evolution of cancer in Africa, as a means of elucidating, confirming, and evaluating causes of the disease. |
| ceo american cancer society: Closing the Cancer Divide Felicia Knaul, Julie Gralow, Rifat A. Atun, Afsan Bhadelia, 2013 Cancer has become a leading cause of death and disability and a serious yet unforeseen challenge to health systems in low-and middle-income countries. A protracted and polarized cancer transition is under way and fuels a concentration of preventable risk, illness, suffering, impoverishment from ill health, and death among poor populations. Closing this cancer divide is an equity imperative. The world faces a huge, unperceived cost of failure to take action that requires an immediate and large-scale global response. Closing the Cancer Divide presents strategies for innovation in delivery, pricing, procurement, finance, knowledge-building, and leadership that can be scaled up by applying a diagonal approach to health system strengthening. The chapters provide evidence-based recommendations for developing programs, local and global policy-making, and prioritizing research. The cases and frameworks provide a guide for developing responses to the challenge of cancer and other chronic illnesses. The book summarizes results of the Global Task Force on Expanding Access to Cancer Care and Control in Developing Countries, a collaboration among leaders from the global health and cancer care communities worldwide, originally convened by Harvard University. It includes contributions from civil society, global and national policy-makers, patients and practitioners, and academics representing an array of fields. |
| ceo american cancer society: The Tobacco Quota Buyout United States. Congress. House. Committee on Agriculture, 2003 |
| ceo american cancer society: Where Did My Money Go? Bob Hopkins, 2012-04-13 Have you ever wondered why you, like most Americans, are broke at the end of every month? Are you a slave to the monthly payment? Do you believe that things in your life would be better if you only got that well-deserved raise? Are you stuck in debt and believe there is no way out and no other way to obtain lifes needs? Did you know one-third of your lifes earnings will go to your house payment as another third goes to pay taxes? Would you like a better way to look at personal finances that will set you free from the shackles of the modern system of debt? Then this could be the very thing you need, as the answers to these questions will be easily explained within. The key to wealth is to be debt free, as commanded by God. Where Did My Money Go? can lead you in that direction by teaching you how to become debt free and recognize the predators knocking on your door in a culture dripping with materialism. Take a journey into a new life free from the banks, finance companies, mortgage companies, college loan companies, and all the other wolves at your door who simply want to take your hard-earned dollar. |
| ceo american cancer society: The Dysautonomia Project Msm Kelly Freeman, MD Phd Goldstein, MD Charles R. Thmpson, 2015-10-05 The Dysautonomia Project is a much needed tool for physicians, patients, or caregivers looking to arm themselves with the power of knowledge. It combines current publications from leaders in the field of autonomic disorders with explanations for doctors and patients about the signs and symptoms, which will aid in reducing the six-year lead time to diagnosis. |
| ceo american cancer society: Never Fear Cancer Again Raymond Francis, 2011-08-01 Most cancer research dollars have been wasted by asking the wrong questions, looking in the wrong places, and recycling the same failed approaches while expecting different results. Conventional cancer treatments damage health, cause new cancers, lower the quality of life, and decrease the chances of survival. In fact, most people who die from cancer are not dying from cancer, but from their treatments! That's the bad news. Here's the good news: We can end the cancer epidemic. In Never Fear Cancer Again, readers will gain a revolutionary new understanding of health and disease and will come to understand that cancer is a biological process that can be turned on and off, not something that can be surgically removed or destroyed with radiation or toxic chemicals. So whether cancer has already been diagnosed or if prevention is the concern, it is possible to turn off the wayward production of these malfunctioning cells once and for all by reading this book and implementing its strategies. The key to any disease has one simple cause: malfunctioning cells that are created by either deficiency or toxicity. By switching off the malfunctioning cells, you switch off the cancer. Never Fear Cancer Again guides readers along six pathways that cause deficiency or toxicity at the cellular level: nutritional path, genetic path, medical path, toxin path, physical path, and the psychological path. By making key lifestyle changes, people truly have the power to take control of cancer and transform their health. This radically different, yet holistic approach restored author Raymond Francis back to health just as it has helped thousands of others, many of whom were told they had no other options or that their cancer was incurable. Take back your health with this book and never fear cancer again. |
| ceo american cancer society: 100 Questions & Answers about Breast Cancer Zora K. Brown, Harold Freeman, Elizabeth Platt, 2007 Written by a doctor and a patient, this book gives both points of view on diagnosis, treatment and support. It answers the 100 most commonly asked questions about breast cancer, in plain English, with explanations of medical terms in the margin on the same page. |
| ceo american cancer society: Orange Coast Magazine , 2007-02 Orange Coast Magazine is the oldest continuously published lifestyle magazine in the region, bringing together Orange County¹s most affluent coastal communities through smart, fun, and timely editorial content, as well as compelling photographs and design. Each issue features an award-winning blend of celebrity and newsmaker profiles, service journalism, and authoritative articles on dining, fashion, home design, and travel. As Orange County¹s only paid subscription lifestyle magazine with circulation figures guaranteed by the Audit Bureau of Circulation, Orange Coast is the definitive guidebook into the county¹s luxe lifestyle. |
| ceo american cancer society: Orange Coast Magazine , 2007-06 Orange Coast Magazine is the oldest continuously published lifestyle magazine in the region, bringing together Orange County¹s most affluent coastal communities through smart, fun, and timely editorial content, as well as compelling photographs and design. Each issue features an award-winning blend of celebrity and newsmaker profiles, service journalism, and authoritative articles on dining, fashion, home design, and travel. As Orange County¹s only paid subscription lifestyle magazine with circulation figures guaranteed by the Audit Bureau of Circulation, Orange Coast is the definitive guidebook into the county¹s luxe lifestyle. |
董事长、总裁和 CEO 的职能有什么区别？ - 知乎
首席执行官（CEO）、总裁（President）：丞相和大将军。通常而言丞相（CEO）是百官之首，但不妨碍部分大将军（总裁）的权力之大可以盖过丞相（例如霍光）。值得一提的是，部分大将军是礼仪性 …
CEO、总裁、总经理这些职务之间有什么区别？电通CEO和其他职 …
ceo是集团化企业或者集群化事业群的企业的经理层最高执行长（首席执行官），对董事会负责，同时要求很高的专业能力和人品。很多人混淆了董事长、总经理、ceo、总裁的对应职务功能，其实主要是 …
执行董事和CEO有什么区别？ - 知乎
Nov 13, 2018 · 执行董事在日常管理中听命于 CEO ，在董事会中参与企业宏观决策。CEO也可能是执行董事，香港有所谓 董事总经理 的称谓就代表CEO也是董事会成员，这不矛盾。 企业员工如果同时是 …
董事长，董事局主席，总裁，CEO 有什么区别？ - 知乎
董事长，董事局主席，总裁，CEO 有什么区别？ 仅限谈谈在大中化地区的差别： 一 董事长 董事局主席. 其实这是一个 外来词的 不同差别 外来词就是：Chairman of the Board. 一般情况表明 他对于一个企 …
创始人、首席执行官、联合创始人、合伙人、CEO分别代表什么含 …
首席执行官，英文CEO或Chief Executive Officer，指企业经营管理主导者，负责企业日常经营管理的全部事务，是一群CXO中权利最大的，相当于过去常说的总经理。CEO由董事会任命和授权，并向董 …
对董事长、总经理等职务，最准确常用的商务英语翻译是什么？
大公司的“大掌柜”： CEO - Chief Executive Officer; President (大企业往往既有CEO 又有 president) 大公司负责日常运作的大掌柜（低于CEO 一级，往往被认为是CEO 的接班人)： COO - Chief …
作为公司管理的三架马车——CEO、COO 和 CFO，哪个高管角色 …
Jul 31, 2017 · 1，ceo的能力有差异，偏管理的估计coo就不重要，偏财务的估计cfo不重要。 2，高科技公司应该至少一人偏向技术。 3，100人以下公司不需要cfo角色，应该ceo兼任。 对于高科技公司， …
CEO 的核心职责是什么？与 COO、CTO、总裁、VP 如何分工？
这两天在 Quora 上出现了一个对CEO在公司中所处角色的讨论，让我们来看看大家都是怎么说的吧： 有人认为一个CEO应该做到三点：1、为公司制定整体战略并与股东沟通；2、为公司招募最出色的人 …
外企职位层级的划分？从低到高，求中英文对照? - 知乎
首席执行官／总裁（CEO／President）：这个级别就不讨论了。对外企来说，这个位子在可以预见的将来还轮不到中国人坐。 此外，外企中常有General Manager（GM）的职位。但这个职位经常是代表 …
GM、VP、FVP、CIO都是什么职位？ - 知乎
CEO(Chief Executive Officer)首席执行官，类似总经理、总裁，是企业的法人代表。 COO(Chief Operations Officer)首席运营官，类似常务总经理 . CFO(Chief Financial Officer)首席财务官，类似财 …
董事长、总裁和 CEO 的职能有什么区别？ - 知乎
首席执行官（CEO）、总裁（President）：丞相和大将军。通常而言丞相（CEO）是百官之首，但不妨碍部分大将军（总裁）的权力之大可以盖过丞相（例如霍光）。值得一提的是，部分大将军是礼仪性 …
CEO、总裁、总经理这些职务之间有什么区别？电通CEO和其他职 …
ceo是集团化企业或者集群化事业群的企业的经理层最高执行长（首席执行官），对董事会负责，同时要求很高的专业能力和人品。很多人混淆了董事长、总经理、ceo、总裁的对应职务功能，其实主要是 …
执行董事和CEO有什么区别？ - 知乎
Nov 13, 2018 · 执行董事在日常管理中听命于 CEO ，在董事会中参与企业宏观决策。CEO也可能是执行董事，香港有所谓 董事总经理 的称谓就代表CEO也是董事会成员，这不矛盾。 企业员工如果同时是 …
董事长，董事局主席，总裁，CEO 有什么区别？ - 知乎
董事长，董事局主席，总裁，CEO 有什么区别？ 仅限谈谈在大中化地区的差别： 一 董事长 董事局主席. 其实这是一个 外来词的 不同差别 外来词就是：Chairman of the Board. 一般情况表明 他对于一个企 …
创始人、首席执行官、联合创始人、合伙人、CEO分别代表什么含 …
首席执行官，英文CEO或Chief Executive Officer，指企业经营管理主导者，负责企业日常经营管理的全部事务，是一群CXO中权利最大的，相当于过去常说的总经理。CEO由董事会任命和授权，并向董 …
对董事长、总经理等职务，最准确常用的商务英语翻译是什么？
大公司的“大掌柜”： CEO - Chief Executive Officer; President (大企业往往既有CEO 又有 president) 大公司负责日常运作的大掌柜（低于CEO 一级，往往被认为是CEO 的接班人)： COO - Chief …
作为公司管理的三架马车——CEO、COO 和 CFO，哪个高管角色 …
Jul 31, 2017 · 1，ceo的能力有差异，偏管理的估计coo就不重要，偏财务的估计cfo不重要。 2，高科技公司应该至少一人偏向技术。 3，100人以下公司不需要cfo角色，应该ceo兼任。 对于高科技公司， …
CEO 的核心职责是什么？与 COO、CTO、总裁、VP 如何分工？
这两天在 Quora 上出现了一个对CEO在公司中所处角色的讨论，让我们来看看大家都是怎么说的吧： 有人认为一个CEO应该做到三点：1、为公司制定整体战略并与股东沟通；2、为公司招募最出色的人 …
外企职位层级的划分？从低到高，求中英文对照? - 知乎
首席执行官／总裁（CEO／President）：这个级别就不讨论了。对外企来说，这个位子在可以预见的将来还轮不到中国人坐。 此外，外企中常有General Manager（GM）的职位。但这个职位经常是代表 …
GM、VP、FVP、CIO都是什么职位？ - 知乎
CEO(Chief Executive Officer)首席执行官，类似总经理、总裁，是企业的法人代表。 COO(Chief Operations Officer)首席运营官，类似常务总经理 . CFO(Chief Financial Officer)首席财务官，类似财 …
